PLR与恶性肿瘤同步放化疗预后的研究进展

doi:10.11904/j.issn.1002-3070.2020.03.016

Abstract

Abstract: At present,for cancer patients who are sensitive to radiotherapy and have no chance of surgery,concurrent chemoradiotherapy is the main treatment.Reasonable radiotherapy efficacy monitoring indicators can provide a reference value for the evaluation of prognosis for cancer patients.Platelet to lymphocyte ratio(PLR)is one of indicators for evaluating body′s inflammatory response.Compared with the lymphocyte and platelet counts alone,PLR can reflect the inflammatory state of patients more accurately and sensitively.The literature has reported the correlation between PLR and malignant tumor radiotherapy and chemotherapy,and has received more and more attention in the evaluation of patient prognosis.This article will review the research progress of PLR in the prognosis of malignant tumor radiotherapy and chemotherapy.

Key words: PLR, Concurrent chemoradiotherapy, Prognosis

CLC Number:

WANG Zhao,FENG Yue,XING Linan,ZHANG Yunyan. Advances in the prognosis of PLR and malignant tumors with concurrent chemoradiotherapy[J]. Journal of Practical Oncology, 2020, 34(3): 271-275.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2020.03.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2020/V34/I3/271

References

1 Wu CC,Li SH,Lu HI,et al.Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy:a propensity score-matched analysis[J].Peer J,2018,6:e5655.
2 Zou J,Yang Y,Yang Y,et al.Polydatin suppresses proliferation and metastasis of non-small cell lung cancer cells by inhibiting NLRP3 inflammasome activation via NF-kappaB pathway[J].Biomed Pharmacother,2018,108:130-136.
3 Unal D,Eroglu C,Kurtul N,et al.Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?[J].Asian Pac J Cancer Prev,2013,14(9):5237-5242.
4 Masjedi A,Hashemi V,Hojjat-Farsangi M,et al.The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer[J].Biomed Pharmacother,2018,108:1415-1424.
5 Mehrazin R,Uzzo RG,Kutikov A,et al.Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma[J].Urol Oncol,2015,33(9):388.319-325.
6 Wang YH,Deng SJ,Yang YD,et al.The pretreatment thrombocytosis may predict prognosis of patients with colorectal cancer:a systematic review and meta-analysis[J].Biomark Med,2017,11(2):195-210.
7 Zhang XJ,Liu YG,Shi XJ,et al.The prognostic role of neutrophils to lymphocytes ratio and platelet count in gastric cancer:a meta-analysis[J].Int J Surg,2015,21:84-91.
8 Guo J,Fang J,Huang X,et al.Prognostic role of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in prostate cancer:a meta-analysis of results from multivariate analysis[J].Int J Surg,2018,60:216-223.
9 Li B,Zhou P,Liu Y,et al.Platelet-to-lymphocyte ratio in advanced cancer:review and meta-analysis[J].Clin Chim Acta,2018,483:48-56.
10 Ma JY,Ke LC,Liu Q.The pretreatment platelet-to-lymphocyte ratio predicts clinical outcomes in patients with cervical cancer:a meta-analysis[J].Medicine(Baltimore),2018,97(43):e12897.
11 Takenaka Y,Oya R,Kitamiura T,et al.Platelet count and platelet-lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma:meta-analysis[J].Head Neck,2018,40(12):2714-2723.
12 Yang HX,Zhang XM,Hao ZP.The diagnostic accuracy of a real-time optoelectronic device in cervical cancer screening:a PRISMA-compliant systematic review and meta-analysis[J].Medicine(Baltimore),2018,97(29):e11439.
13 Smith RA,Bosonnet L,Raraty M,et al.Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma[J].Am J Surg,2009,197(4):466-472.
14 Rao AK,Rao DA.Platelets signal and tumors take off[J].Blood,2012,120(24):4667-4668.
15 Wu T,Li Y,Lu J,et al.Increased MMP-21 expression is associated with poor overall survival of patients with gastric cancer[J].Med Oncol,2013,30(1):323.
16 Dunn GP,Bruce AT,Ikeda H,et al.Cancer immunoediting:from immunosurveillance to tumor escape[J].Nat Immunol,2002,3(11):991-998.
17 Mantovani A,Allavena P,Sica A,et al.Cancer-related inflammation[J].Nature,2008,454(7203):436-444.
18 Stotz M,Gerger A,Eisner F,et al.Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer[J].Br J Cancer,2013,109(2):416-421.
19 Zhang J,Huang SH,Li H,et al.Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer[J].Med Oncol,2013,30(1):352.
20 Siegel RL,Miller KD,Jemal A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
21 Onal C,Guler OC,Yildirim BA.Prognostic use of pretreatment hematologic parameters in patients receiving definitive chemoradiotherapy for cervical cancer[J].Int J Gynecol Cancer,2016,26(6):1169-1175.
22 Lee JW,Jeon S,Mun ST,et al.Prognostic value of fluorine-18 fluorodeoxyglucose uptake of bone marrow on positron emission tomography/computed tomography for prediction of disease progression in cervical cancer[J].Int J Gynecol Cancer,2017,27(4):776-783.
23 Holub K,Biete A.Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients[J].Clin Transl Oncol,2019,21(7):836-844.
24 Haraga J,Nakamura K,Omichi C,et al.Pretreatment prognostic nutritional index is a significant predictor of prognosis in patients with cervical cancer treated with concurrent chemoradiotherapy[J].Mol Clin Oncol,2016,5(5):567-574.
25 Bond-Smith G,Banga N,Hammond TM,et al.Pancreatic adenocarcinoma[J].BMJ,2012,344:e2476.
26 Konstantinidis IT,Warshaw AL,Allen JN,et al.Pancreatic ductal adenocarcinoma:is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?[J].Ann Surg,2013,257(4):731-736.
27 Lee BM,Chung SY,Chang JS,et al.The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are prognostic factors in patients with locally advanced pancreatic cancer treated with chemoradiotherapy[J].Gut Liver,2018,12(3):342-352.
28 刘建辉,罗妍,陈晓,等.放疗前中性粒细胞/淋巴细胞血小板/淋巴细胞预后营养指数及CA19-9与胰腺腺癌放疗后预后关系的分析[J].中国肿瘤临床,2017,44(6):289-293.
29 Dongwook O,Jung-Soo P,Kuan SD.Prognostic roles of inflammatory markers in pancreatic cancer:comparison between the neutrophil-to-Lymphocyte ratio and platelet-to-lymphocyte ratio[J].Gastroenterol Res Pract,2018,2018:9745601.
30 Zeng H,Zheng R,Guo Y,et al.Cancer survival in China,2003-2005:a population-based study[J].Int J Cancer,2015,136(8):1921-1930.
31 Miao C,Zhu S,Pan H,et al.Combined neutrophil-platelet score and hemoglobin level predict survival in esophageal squamous cell carcinoma patients treated with chemoradiotherapy[J].Oncotarget,2017,8(50):87971-87979.
32 Zhu S,Miao CW,Wang ZT,et al.Sensitivity value of hematological markers in patients receiving chemoradiotherapy for esophageal squamous cell carcinoma[J].Onco Targets Ther,2016,9:6187-6193.
33 Tang Y,Li G,Wu S,et al.Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy:prognostic significance and association with inflammatory biomarkers[J].Oncol Lett,2018,15(4):4988-4996.
34 Vansteenkiste J,De Ruysscher D,Eberhardt WE,et al.Early and locally advanced non-small-cell lung cancer(NSCLC):ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2013,24(Suppl 6):89-98.
35 NSCLC Meta-analysis Collaborative Group.Preoperative chemotherapy for non-small-cell lung cancer:a systematic review and meta-analysis of individual participant data[J].Lancet,2014,383(9928):1561-1571.
36 Stinchcombe TE,Zhang Y,Vokes EE,et al.Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US National Cancer Institute Cooperative Group Studies[J].J Clin Oncol,2017,35(25):2885-2892.
37 Antoni D,Mornex F.Chemoradiotherapy of locally advanced nonsmall cell lung cancer:state of the art and perspectives[J].Curr Opin Oncol,2016,28(2):104-109.
38 Pless M,Stupp R,Ris HB,et al.Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer:a phase 3 randomised trial[J].Lancet,2015,386(9998):1049-1056.
39 Tong YS,Tan J,Zhou XL,et al.Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer[J].J Transl Med,2017,15(1):221.
40 Cannon NA,Meyer J,Iyengar P,et al.Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer[J].J Thorac Oncol,2015,10(2):280-285.
41 Shaverdian N,Veruttipong D,Wang J,et al.Pretreatment immune parameters predict for overall survival and toxicity in early-stage non-small-cell lung cancer patients treated with stereotactic body radiation therapy[J].Clin Lung Cancer,2016,17(1):39-46.
42 Kano S,Homma A,Hatakeyama H,et al.Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer[J].Head Neck,2017,39(2):247-253.
43 Sun W,Zhang L,Luo M,et al.Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma:neutrophil-lymphocyte ratio and platelet-lymphocyte ratio[J].Head Neck,2016,38(Suppl 1):1332-1340.
44 Ye L,Oei RW,Kong F,et al.Prognostic values of hematological biomarkers in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy[J].Eur Arch Otorhinolaryngol,2018,275(5):1309-1317.

[1]	XIE Xianxin,WEI Jun,QIU Jiaxin,WANG Cong,JIANG Daqing. Analysis of histopathological information and prognosis of residual tumor in neoadjuvant chemotherapy for breast cancer [J]. Journal of Practical Oncology, 2020, 34(3): 225-231.
[2]	SU Wenjia, WANG Shuye. Prognostic stratification and treatment progress of follicular lymphoma [J]. Journal of Practical Oncology, 2020, 34(2): 189-192.
[3]	LIAO Daixiang, ZHENG Bo, ZHANG Yanbin, YU Junhui. Expression of RRBP1 and RABEX-5 proteins in colorectal cancer and their correlation with clinicopathological features and prognosis [J]. Journal of Practical Oncology, 2020, 34(1): 43-48.
[4]	LIU Gengchun, SHEN Liangfang. Relationship between serum long-chain non-coding RNA MALAT1 and AFAP1-AS1,and clinicopathological features and prognosis of nasopharyngeal carcinoma [J]. Journal of Practical Oncology, 2019, 33(6): 513-518.
[5]	FAN Jinhai, JIANG Yumei, ZHANG Jing, BAI Xiaojing. Expression of MAP1A in bladder cancer and its correlation with clinicopathological features [J]. Journal of Practical Oncology, 2019, 33(6): 525-530.
[6]	LIU Siwei, CUI Yue, SUN Yuanyuan, HU Jing, ZHANG Wenrui, CAO Mengru. Effect of FOXD3 in lung cancer cells [J]. Journal of Practical Oncology, 2019, 33(5): 390-396.
[7]	XIA Tianyi, ZHANG Bomiao, YAO Kefei, CUI Binbin. Clinical relationship between PTPN9 expression and colorectal cancer [J]. Journal of Practical Oncology, 2019, 33(5): 415-419.
[8]	XU Ting, YAN Feifei, ZHANG Chunhui, ZHANG Yanqiao. Analysis of clinical pathology and prognosis in patients with gastric cancer & bone metastasis [J]. Journal of Practical Oncology, 2019, 33(5): 436-441.
[9]	LI Siwei, PANG Da. Long non-coding RNA(lncRNA)role in cancer [J]. Journal of Practical Oncology, 2019, 33(5): 471-475.
[10]	QU Yanfei, LIU Chao, WANG Bojun, FANG Lin, ZHANG Yanqiao. Expression of CSN6 gene in hepatocellular carcinoma tissues and its clinical significance [J]. Journal of Practical Oncology, 2019, 33(4): 328-333.
[11]	LIU Jintao, GAO Ling, ZHOU Huiui. Expression of MAGEA4 and EB1 proteins in lung cancer tissues and their correlation with clinicopathological features and prognosis [J]. Journal of Practical Oncology, 2019, 33(4): 334-339.
[12]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[13]	FENG Yue,XING Linan,WANG Zhao,ZHANG Yunyan. Correlation between NLR and prognosis of concurrent chemoradiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 284-288.
[14]	BAI Xiaobin, HUO Longwei, XIE Wanfu, XU Gaofeng, WANG Maode. Expression of Chk1 in glioblastoma and its association with tumor biological behavior and prognosis survival [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 122-127.
[15]	SHI Xiaokang, DING Youming, WANG Bin, YU Bin, XU Yu. Expression and clinical significance of UBE2T in primary liver cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 128-133.

Advances in the prognosis of PLR and malignant tumors with concurrent chemoradiotherapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments